HomeCompareSTMM vs ORCC

STMM vs ORCC: Dividend Comparison 2026

STMM yields 3333.33% · ORCC yields 9.79%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 STMM wins by $1244041712890.38M in total portfolio value
10 years
STMM
STMM
● Live price
3333.33%
Share price
$0.06
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$1244041712890.40M
Annual income
$1,174,716,366,071,938,000.00
Full STMM calculator →
ORCC
ORCC
● Live price
9.79%
Share price
$13.48
Annual div
$1.32
5Y div CAGR
-50%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$21.4K
Annual income
$1.04
Full ORCC calculator →

Portfolio growth — STMM vs ORCC

📍 STMM pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodSTMMORCC
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, STMM + ORCC cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
STMM pays
ORCC pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

STMM
Annual income on $10K today (after 15% tax)
$283,333.33/yr
After 10yr DRIP, annual income (after tax)
$998,508,911,161,147,300.00/yr
ORCC
Annual income on $10K today (after 15% tax)
$832.34/yr
After 10yr DRIP, annual income (after tax)
$0.88/yr
At 15% tax rate, STMM beats the other by $998,508,911,161,147,300.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of STMM + ORCC for your $10,000?

STMM: 50%ORCC: 50%
100% ORCC50/50100% STMM
Portfolio after 10yr
$622020856445.21M
Annual income
$587,358,183,035,969,000.00/yr
Blended yield
94.43%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ORCC right now

STMM
No analyst data
ORCC
Analyst Ratings
9
Buy
4
Hold
1
Sell
Consensus: Buy
Price Target
$16.00
+18.7% upside vs current
Range: $16.00 — $16.00
Altman Z
0.5
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

STMM buys
0
ORCC buys
0
No recent congressional trades found for STMM or ORCC in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricSTMMORCC
Forward yield3333.33%9.79%
Annual dividend / share$2.00$1.32
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%-50%
Portfolio after 10y$1244041712890.40M$21.4K
Annual income after 10y$1,174,716,366,071,938,000.00$1.04
Total dividends collected$1239274250481.68M$1.0K
Payment frequencyquarterlyquarterly
SectorStockBDC

Year-by-year: STMM vs ORCC ($10,000, DRIP)

YearSTMM PortfolioSTMM Income/yrORCC PortfolioORCC Income/yrGap
1← crossover$344,033$333,333.33$11,190$489.61+$332.8KSTMM
2$11,085,665$10,717,549.33$12,229$256.01+$11.07MSTMM
3$334,616,633$322,754,971.08$13,216$130.74+$334.60MSTMM
4$9,462,934,690$9,104,894,892.71$14,207$66.02+$9462.92MSTMM
5$250,766,259,005$240,640,918,887.41$15,234$33.17+$250766.24MSTMM
6$6,228,082,462,189$5,959,762,565,053.11$16,317$16.62+$6228082.45MSTMM
7$144,998,525,500,125$138,334,477,265,582.72$17,468$8.32+$144998525.48MSTMM
8$3,165,074,899,913,431$3,009,926,477,628,297.00$18,695$4.16+$3165074899.89MSTMM
9$64,790,043,755,570,470$61,403,413,612,663,110.00$20,006$2.08+$64790043755.55MSTMM
10$1,244,041,712,890,398,500$1,174,716,366,071,938,000.00$21,407$1.04+$1244041712890.38MSTMM

STMM vs ORCC: Complete Analysis 2026

STMMStock

Stemcell Holdings, Inc., through its subsidiary, Stemcell Co., Ltd., engages in the regenerative medicine-related business. It provides technical assistance services to the culturing, storing, and delivery of stem cells; and administrative and consulting services to clinics. The company offers two different options for stem cell regenerative therapy, including autologous adipose derived mesenchymal stem cells and natural killer cells. It also provides coordination services to facilitate its stem cell culturing business, which comprise the introduction of patients to clinics, arranging patients' schedules, and translating between patients and clinics due to language barriers. In addition, Stemcell Holdings, Inc. offers Internet marketing services through search engine optimization for clinics; and property and equipment rental services. The company was formerly known as Perfect Acquisition, Inc., and changed its name to Stemcell Holdings, Inc. in January 2016. Stemcell Holdings, Inc. was founded in 2015 and is based in Tokyo, Japan. as of May 2, 2016, Stemcell Holdings, Inc. operates as a subsidiary of Primavera Singa Pte Ltd.

Full STMM Calculator →

ORCCBDC

Owl Rock Capital Corporation is a business development company. The fund makes investments in senior secured or unsecured loans, subordinated loans or mezzanine loans and also considers equity-related securities including warrants and preferred stocks also pursues preferred equity investments and common equity investments. Within private equity, it seeks to invest in growth, acquisitions, market or product expansion, refinancings and recapitalizations. It seeks to invest in middle market companies based in the United States, with EBITDA between $10 million and $250 million annually and/or annual revenue of $50 million and $2.5 billion at the time of investment.

Full ORCC Calculator →
📬

Get this STMM vs ORCC comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

STMM vs SCHDSTMM vs JEPISTMM vs OSTMM vs KOSTMM vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.